Quiet on the insider front: nobody at Regulus Therapeutics Inc. bought or sold RGLS shares in open-market trades this past year.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | Klassen Preston | President | Buy | 12,000 | $7.99 | $96K | SEC |
| Jan 31, 2025 | Hagan Joseph P | CEO | Buy | 50,000 | $1.09 | $54K | SEC |
| Jan 31, 2025 | BALTIMORE DAVID | Director | Buy | 19,610 | $1.06 | $21K | SEC |
| Jan 15, 2025 | Hagan Joseph P | CEO | Sell | 115,290 | $1.26 | $145K | SEC |
| Jan 15, 2025 | Hagan Joseph P | CEO | Sell | 11,764 | $1.26 | $15K | SEC |
| Jan 15, 2025 | Aker Christopher Ray | Executive Officer | Sell | 38,547 | $1.26 | $49K | SEC |
| Jan 15, 2025 | Aker Christopher Ray | Executive Officer | Sell | 5,088 | $1.26 | $6K | SEC |
| Jan 15, 2025 | CALSADA CRISPINA | CFO | Sell | 5,088 | $1.26 | $6K | SEC |
| Jan 15, 2025 | CALSADA CRISPINA | CFO | Sell | 38,716 | $1.26 | $49K | SEC |
| Jan 15, 2025 | Klassen Preston | President | Sell | 31,445 | $1.26 | $40K | SEC |
| Jul 29, 2024 | Collier Kathryn J | Director | Buy | 4,000 | $1.82 | $7K | SEC |
| Jan 18, 2024 | CALSADA CRISPINA | CFO | Sell | 5,468 | $1.19 | $7K | SEC |
| Jan 18, 2024 | Aker Christopher Ray | Executive Officer | Sell | 5,468 | $1.19 | $7K | SEC |
| Jan 18, 2024 | Hagan Joseph P | CEO | Sell | 14,580 | $1.19 | $17K | SEC |
There were no open-market insider trades in RGLS in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in RGLS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).